KyungDong Pharm home
Prescription Medicines

Pictos Tab.

Product Category
Oral hypoglycemic agents
Active Ingredients
pioglitazone hydrochloride
Appearance
A white or pale yellow, round tablet.
Reimbursement Code
648102380
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Pioglitazone hydrochloride (USP)----16.53mg (15mg as pioglitazone)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Magnesium stearate, calcium carboxymethyl cellulose, hydroxypropyl cellulose

2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.

1. This drug is administered as monotherapy.
2. This drug is administered as combination therapy in the following cases.
If the effect of improving blood sugar level is not seen despite using other oral hypoglycemic agents, concurrent administration with sulfonylurease, metformin, or insulin

Type 2 diabetic patients also require nutritional counseling and, in some cases, weight loss. Exercise therapy should also be performed. For patients with type 2 diabetes, these efforts are important not only for initial treatment but also for maintaining the effectiveness of drug therapy.

3. Dosage and dosage
This drug is administered orally once a day, regardless of meal.
Diabetes management must be individually differentiated for each person. The most ideal method is to evaluate the response to treatment by looking at the glycated hemoglobin (HbA1c) level, which is a more accurate diagnostic method than fasting blood sugar (FBG). Glycated hemoglobin reflects blood sugar status over the past 2 to 3 months. Clinically, this drug should be administered to diabetic patients for an appropriate period of time (at least 3 months) to evaluate changes in glycated hemoglobin if glycemic control does not worsen. Administration to children under 18 years of age is not recommended as there is no experience with its use.

1. Monotherapy
This drug can be started at 15 mg once daily as pioglitazone as monotherapy in patients whose blood sugar level is not adequately controlled by diet and exercise therapy. If the initial dose of this drug does not provide sufficient effect, the dose can be increased up to 30 mg once a day. Combination therapy should be considered for patients who do not respond adequately to monotherapy.

2. Combination therapy
1) Sulfonylurea: This drug can be administered in combination with sulfonylurea drugs, and the initial dose is 15 mg once a day. When used in combination with this drug, current sulfonylurea drugs can be administered continuously at the same dosage.
However, if the patient shows symptoms of hypoglycemia, the sulfonylurea dosage should be reduced.

2) Metformin: This drug can be administered in combination with metformin, and the initial dose is 15 mg once a day. When used in combination with this drug, the current metformin can be administered continuously at the same dosage. It is unlikely that metformin doses will need to be adjusted due to episodes of hypoglycemia during combination therapy with this drug.

3) Insulin: This drug can be administered in combination with insulin, and the dose is 15 mg once a day. This drug allows the current insulin dose to be maintained continuously even when combination therapy is started. However, if a patient receiving this drug and insulin in combination shows symptoms of hypoglycemia or the plasma glucose concentration decreases below 100 mg/dL, the insulin dose can be reduced by 10 to 25%. Subsequent dosage adjustments are individually adjusted depending on the state of blood sugar control.

• Maximum recommended dose
For monotherapy or combination therapy with sulfonylureas, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dosage adjustment in patients with renal insufficiency is not recommended (see General Precautions in Patients with Renal Impairment).
At the start of treatment, if the patient shows clinical evidence of active liver disease or increased serum transaminase levels (more than 2.5 times the upper limit of normal ALT), treatment with this drug should not be started (see Actions on the liver in Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting therapy with this drug and periodically thereafter. There are no data on administering this drug in combination with other thiozolidinedione.

4. Precautions for use
1. Warning
1) Thiazolidinedione drugs, including this drug, may cause or worsen congestive heart failure in some patients. After initiating treatment with this drug or increasing the dosage, patients should be carefully observed for symptoms and signs of heart failure (including excessive and rapid weight change, dyspnea, and edema). If these symptoms and signs appear, heart failure should be managed according to current standard treatment regimens. Additionally, discontinuation or reduction of the dose of this drug should be considered.
2) Patients with heart failure should not begin treatment with this drug. Administration of this drug in patients with symptomatic heart failure is not recommended.
3) Heart failure and other actions on the heart
This drug, like other thiazolidinediones, may cause fluid retention when administered alone or in combination with other anti-diabetic drugs such as insulin. Fluid retention can cause or worsen heart failure. Patients should be monitored for signs and symptoms of heart failure (see Information for Patients under General Precautions). When these symptoms and signs occur, heart failure should be managed according to current standard treatments. Additionally, discontinuation or dose reduction of this drug should be considered.
In a 16-week, double-blind, placebo-controlled clinical trial in the United States involving 566 patients with type 2 diabetes, the combination therapy of insulin and 15 mg and 30 mg of this drug was compared with insulin monotherapy. This clinical trial included patients with long-standing diabetes and pre-existing medical conditions with a high prevalence of: : arterial hypertension (57.2%), peripheral neuropathy (22.6%), coronary artery disease (19.6%), retinopathy (13.1%), myocardial infarction (8.8%), vascular disease (6.4%), angina (4.4%), stroke and/or transient ischemic attack (4.1%), and congestive heart failure (2.3%).
In this study, 2 of 191 patients (1.0%) receiving 15 mg of sulfide plus insulin and 2 (1.1%) of 188 patients receiving 30 mg of sulfate plus insulin developed congestive heart failure, compared with none of 187 patients on insulin alone. All four patients had a history of cardiovascular abnormalities, including coronary artery disease, previous CABG procedures, and myocardial infarction. Additionally, in a 24-week dose-adjustment study in which this drug was administered in combination with insulin, 0.3% (1/345) of the 30 mg dose group and 0.9% (3/345) of the 45 mg dose group reported congestive heart failure as a serious adverse reaction.
From the data analyzed in this study, no specific factors were identified that could predict an increased risk of congestive heart failure during combination therapy with insulin.
A cardiovascular outcome trial of pioglitazone was conducted in patients younger than 75 years of age with type 2 diabetes and pre-existing major macrovascular disease. This drug or placebo was administered for up to 3.5 years in addition to existing antidiabetic and cardiovascular therapy. This trial showed an increase in reporting of heart failure, but this did not result in an increase in mortality in this trial. Because experience with this patient population is limited, it should be used with caution in patients over 75 years of age.
4) Prospective pioglitazone clinical trial for cases of macrovascular complications (PROactive)
In PROactive, 5,238 patients with type 2 diabetes and a previous history of macrovascular disease were given force-titration of this drug (2,605 patients) up to 45 mg once daily or placebo (2,633 patients) (see Adverse Reactions section). The proportion of patients who developed serious heart failure was higher in patients receiving this drug (5.7%, 149 patients) than in patients receiving placebo (4.1%, 108 patients). Following reports of serious heart failure, the incidence of death was 1.5% (40 patients) in patients receiving this drug and 1.4% (37 patients) in patients receiving placebo. At baseline, the incidence of serious heart failure was 6.3% (54/864) in patients taking this drug and insulin and 5.2% (47/896) in placebo. The incidence of serious heart failure in patients receiving this drug and sulfonylurea was 5.8% (94/1,624), compared to 4.4% (71/1,626) in placebo.
5) If signs of gross hematuria or other symptoms such as dysuria or urgency appear or increase during treatment, the patient should be instructed to immediately notify the doctor, as these symptoms may be due to bladder cancer.

2. Do not administer to the following patients.
1) Patients with known hypersensitivity to this drug or its components
2) Patients with heart failure or patients with a history of heart failure (in animal experiments, an increase in weight, which is thought to be a compensatory change accompanied by an increase in circulating plasma volume, was observed, and clinically, there are reports that it worsened or developed heart failure.)
3) Patients with active bladder cancer or patients with a history of bladder cancer
4) Patients with liver impairment
5) Patients with severe renal impairment
6) Patients with diabetic ketoacidosis, diabetic coma and precoma, and type 1 diabetes patients
7) Before and after surgery, patients with severe infections, and patients with severe trauma (administration of this drug is not appropriate as blood sugar control through insulin injection is preferred.)
8) Patients with unirradiated gross hematuria
9) Women who are pregnant or may be pregnant
10) Since this drug contains lactose in tablets, patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (limited to products containing lactose)

3. Administer with caution to the following patients (cases):
1) Patients taking other oral hypoglycemic agents
2) Premenopausal women
3) Patients with edema
4) Patients with heart diseases such as myocardial infarction, angina pectoris, cardiomyopathy, and hypertensive heart disease at risk of developing heart failure (there is a risk of developing heart failure due to an increase in circulating plasma volume).
5) Patients with renal dysfunction
6) Patients with pituitary dysfunction or adrenal dysfunction
7) Malnutrition, starvation, irregular meal intake, insufficient meal intake, or weakness (may cause hypoglycemia).
8) Vigorous muscle exercise (may cause hypoglycemia)
9) Excessive alcohol consumption (may cause hypoglycemia)
10) Elderly people

4. Adverse reactions
1) Foreign clinical trials and post-marketing surveillance
(1) More than 8,500 patients with type 2 diabetes received this drug in randomized, double-blind, controlled clinical trials, including 2,605 patients with type 2 diabetes and macrovascular disease who received this drug in the PROactive clinical trial. In these clinical trials, more than 6,000 patients received this drug for at least 6 months, more than 4,500 patients received this drug for more than 1 year, and more than 3,000 patients received this drug for at least 2 years.
When combining six placebo-controlled monotherapy trials of 16 to 26 weeks and combination therapy trials of 16 to 24 weeks, the incidence of study discontinuation due to adverse reactions was 4.5% for patients receiving this drug and 5.8% for patients receiving the reference drug. The most common adverse reactions leading to study discontinuation were related to inadequate glycemic control, but the incidence of these adverse reactions was lower with ZELJANZ (1.5%) compared to placebo (3.0%).
In the PROactive clinical trial, the incidence of study discontinuation due to adverse events was 9.0% for patients receiving this drug and 7.7% for patients receiving placebo. Congestive heart failure was the most common serious adverse event leading to discontinuation of the study, occurring in 1.3% of patients receiving this drug and 0.6% of patients receiving placebo.
(2) Common adverse reactions: 16-26 week monotherapy clinical trial
Table 1 shows the incidence and types of common adverse reactions reported when combining three placebo-controlled monotherapy clinical trials for this drug for 16 to 26 weeks. The reactions summarized below represent adverse reactions that occurred in >5% of cases and those that occurred more commonly in patients receiving this drug compared to patients receiving placebo. None of these adverse reactions were related to the dose of this drug (see appendix for further details).
(3) Common adverse reactions: 16-24 week combination therapy clinical trial
The overall incidence and types of common adverse reactions reported in clinical trials in which this drug was administered in combination with sulfonylurea are shown in Table 2. The reactions summarized below represent adverse reactions that occurred in >5% of cases and those that occurred more commonly in patients receiving this drug at the highest dose tested (see appendix for further details).
(4) The overall incidence and types of common adverse reactions reported in clinical trials in which this drug was administered in combination with metformin are shown in Table 3. The reactions summarized below represent those that occurred in >5% of cases and those that occurred more commonly in patients receiving this drug at the highest dose tested. (Please refer to the attached document for more details)
(5) Table 4 shows the incidence and types of common adverse reactions reported in clinical trials in which this drug was administered in combination with insulin. The reactions summarized below represent those that occurred in >5% of patients and those that occurred more commonly in patients receiving this drug at the highest dose tested. (Please refer to the attached document for more details)
(6) The overall incidence and types of common adverse reactions reported in PROactive clinical trials are shown in Table 5. The reactions summarized below represent adverse reactions that occurred in greater than 5% of cases and occurred more commonly in patients treated with this drug compared to patients treated with placebo. (Please refer to the attached document for more details)
(7) Congestive heart failure: The incidence of adverse reactions related to congestive heart failure for clinical trials using sulfonylurea in combination for 16 to 24 weeks, clinical trials using insulin in combination for 16 to 24 weeks, and metformin for 16 to 24 weeks are shown in Table 6. None of these adverse reactions were fatal. (Please refer to the attached document for more details)
(8) Patients with type 2 diabetes and NYHA class 2 or 3 (early stage) congestive heart failure were randomly assigned to receive 30 to 45 mg of this drug per day (n = 262) or 10 to 15 mg of glyburide per day (n = 256) for 24 weeks in a double-blind manner. The incidence of congestive heart failure-related adverse reactions reported in this clinical trial is shown in Table 7. (Please refer to the attached document for further details.)
(9) Cases of congestive heart failure resulting in hospitalization that occurred during the PROactive clinical trial are listed in Table 8. (Please refer to the attached document for further details.)
(10) Cardiovascular safety: In the PROactive clinical trial, 5,238 patients with type 2 diabetes with a history of macrovascular disease were randomly assigned to a test group that administered this drug in addition to standard therapy (n = 2,605), a test group that administered this drug by forced titration up to a daily dose of 45 mg, or a placebo group (n = 2,633). Almost all patients (95%) were receiving cardiovascular drugs (beta-blockers, ACE inhibitors, angiotensin II receptor blockers, potassium channel blockers, nitrate agents, diuretics, aspirin, statins, and fibrates). The average age of the patients at the start of the study was 62 years, the average duration of diabetes was 9.5 years, and the average glycated hemoglobin (HbA1c) was 8.1%. The average follow-up period was 34.5 months.
The primary objective of this trial was to investigate the effect of this drug on mortality and macrovascular morbidity in patients with type 2 diabetes who are at high risk for macrovascular complications. The primary efficacy variable was the time to the first event of any of the following cardiovascular composite endpoints, which included all-cause death, non-fatal myocardial infarction (MI), stroke, acute coronary syndrome, cardiovascular intervention including coronary artery bypass grafting (CABG) or percutaneous intervention (PCI), major lower extremity amputation above the ankle, and bypass surgery or vascular reconstruction of the lower extremity. A total of 514 (19.7%) subjects who received this drug and 572 (21.7%) who received placebo experienced at least one event of the primary composite endpoint (risk ratio 0.90; 95% confidence interval: 0.80, 1.02; p = 0.10).
There was no statistically significant difference between ZEROLYX and placebo in the 3-year incidence of first events for any of these composite variables, but there was no increase in ADVERTISEMENT-related deaths or total macrovascular complications. The number of first occurrences and total number of individual cases for cases contributing to the primary composite endpoint are shown in Table 9. (Please refer to the attached document for more details)
(11) Weight gain: Dose-related weight gain occurred when this drug was used alone or in combination with other antidiabetic drugs. The mechanism of weight gain is unclear, but likely involves a combination of fluid retention and fat accumulation.
Weight changes for this drug and placebo in the 16-26 week randomized, double-blind monotherapy clinical trial, the 16-24 week combination therapy clinical trial, and the PROactive clinical trial are shown in Tables 10 and 11. (Please refer to the attached document for details.)
(12) Edema: Edema caused by taking this drug is reversible when this drug is discontinued. Hospitalization due to edema is not necessary unless the patient also suffers from congestive heart failure. The frequency and types of edema-related adverse reactions that occurred in clinical studies of this drug are listed in Table 12. (Please refer to the attached document for further details.)
(13) Action on the liver: There has been no evidence of hepatotoxicity caused by this drug in the controlled clinical trial data to date. One randomized, double-blind, 3-year clinical trial was specifically designed to evaluate the incidence of serum ALT elevations above 3 times the upper limit of the normal range when serum ALT levels were measured every 8 weeks for the first 48 weeks of the trial and every 12 weeks thereafter, comparing Glyburide in combination with metformin and insulin therapy. A total of 3 (0.3%) out of 1,051 subjects who received this drug and 9 (0.9%) out of 1,046 subjects who received glyburide showed ALT levels exceeding 3 times the upper limit of the normal range. To date, in the controlled clinical trial data on this drug, no subjects treated with this drug have had serum ALT levels exceeding 3 times the upper limit of the normal range and corresponding total bilirubin levels exceeding 2 times the upper limit of the normal range (the combination of which suggests the possibility of severe drug-induced liver injury).
(14) Hypoglycemia: In clinical trials of this drug, adverse reactions to hypoglycemia were reported based on the clinical judgment of the investigator, and confirmation with a fingerstick glucose test was not required.
In a 16-week trial of coadministration with a sulfonylurea, hypoglycemia was reported in 3.7% of patients receiving this medicine at 30 mg and 0.5% receiving placebo. In a 16-week trial of coadministration with insulin, the reported incidence was 7.9% with 15 mg, 15.4% with 30 mg, and 4.8% with placebo.
The reported incidence of hypoglycemia was higher with the 45 mg dose compared to 30 mg in both the 24-week trial with sulfonylurea (15.7% vs. 13.4%) and the 24-week trial with combination use with insulin (47.8% vs. 43.5%).
In these four trials, three subjects were hospitalized due to hypoglycemia. All three subjects were receiving 30 mg (0.9%) of this drug in a 24-week clinical trial in combination with insulin. An additional 14 subjects reported severe hypoglycemia (defined as causing significant impairment of the subject's usual activities) that did not require hospitalization. These subjects were receiving 45 mg of this drug in combination with a sulfonylurea (2 patients) or 30 mg or 45 mg of this drug in combination with insulin (12 patients).
(15) Bladder cancer: As a result of a 2-year carcinogenicity test, bladder tumors were observed in male rats. In two 3-year clinical trials of this drug using placebo or glyburide as comparators, bladder cancer was reported in 5 out of 3,679 patients (0.14%) who did not take this drug, and in 16 out of 3,656 patients (0.44%) who took this drug. After excluding patients who had been exposed to the test drug for less than 1 year at the time of bladder cancer diagnosis, there were 6 cases (0.16%) for this drug and 2 cases (0.05%) for placebo. Because the number of cases of bladder cancer was extremely small, the causal relationship could not be confirmed.
(16) Effect on clinical test values
① Hematology: This drug may cause a decrease in hemoglobin and hematocrit. In placebo-controlled monotherapy clinical trials, the average hemoglobin level change in patients receiving placebo was -1% to +1%, while the average hemoglobin level change in patients receiving this drug decreased to 2% to 4%. These changes mainly occurred within the first 4 to 12 weeks after starting treatment and remained relatively constant thereafter. These changes may be related to the increase in plasma volume associated with treatment with this drug and are unlikely to be associated with clinically significant hematological effects.
② Creatine Kinase (CK) Level: During clinical trials, while serum creatine kinase (CK) was measured as specified in the clinical trial protocol, a CK-only increase exceeding 10 times the upper limit of the normal range was observed in 9 subjects (0.2%) who received this drug (level = 2,150 ~ 11,400 IU/L), and was not observed in subjects who received the control drug. didn't Of these patients, 6 continued treatment with this drug, 2 had an increase in CK on the last day of treatment, and 1 patient discontinued the study drug due to an increase in this value. These increases resolved without notable clinical sequelae. The relationship between these reactions and this drug therapy is unknown.
2) Post-marketing experience
The following adverse reactions were identified during the period of post-marketing use of this drug. Because these adverse reactions are voluntarily reported from a population of uncertain size, it is generally not possible to reliably estimate their incidence or establish a causal relationship with drug exposure.
• Onset or worsening of diabetic macular edema with decreased vision.
• Fatal and non-fatal liver failure
Post-marketing reports of congestive heart failure have been reported in patients treated with this drug, both with and without a prior history of cardiac disease, and in patients treated with or without concomitant insulin.
In post-marketing experience, there have been reports of unusually rapid weight gain exceeding that typically observed in clinical trials. Patients who experience this weight gain should be evaluated for fluid accumulation and volume-related events, such as excessive edema and congestive heart failure.

3) Domestic post-marketing survey
(1) As a result of the post-marketing use results survey conducted on 13,454 people for re-examination in Korea, the occurrence rate of adverse events was reported to be 2.80% (377/13,454 people, 445 cases) regardless of causal relationship, of which adverse cardiovascular events were 1.37% (184/13,454 people). Adverse drug cases for which a causal relationship with this drug cannot be ruled out were 1.58% (212 people/13,454 people, 236 cases), including edema 0.54% (73 people/13,454 people, 74 cases), weight gain 0.46% (62 people/13,454 people, 62 cases), and hypoglycemia. 0.13% (17 people/13,454 people, 17 cases), dizziness 0.07% (9 people/13,454 people, 9 cases), upper respiratory infection 0.03% (4 people/13,454 people, 4 cases), increased blood sugar 0.04% (6 people/13,454 people, 6 cases), ALT/AST elevation 0.03 % (4 people/13,454 people), loss of appetite, constipation, upper abdominal pain, headache 0.02% (3 people/13,454 people, 3 cases), chest pain, fatigue, weakness, indigestion, nausea, difficulty breathing, itching 0.01% (2 people/13,454 people, 2 cases), chest discomfort, tremors, chills, gastrointestinal disease, abdominal pain, solar plexus discomfort, Numbness, tremors, muscle stiffness, head discomfort, increased liver enzymes, worsening liver disease, hives, eczema, joint pain, knee abnormalities, weakness in the arms, proteinuria, increased blood creatinine, anxiety, insomnia, drowsiness, herpes simplex, blurred vision, high blood pressure, loss of heart function, orthostatic hypotension, palpitations, stroke, sexual dysfunction, and myocardial infarction. Among these, serious adverse drug events included edema, worsening liver disease, knee abnormalities, and stroke (0.01% each) (1 person/13,454 people, 1 case). New drug adverse events that did not appear in pre-marketing clinical trials were 0.41% (55 people/13,454 people, 63 cases), dizziness at 0.07% (9 people/13,454 people, 9 cases), anorexia, constipation, upper abdominal pain at 0.0% (3 people/13,454 people, 3 cases), chest pain, fatigue, weakness, indigestion, nausea, cough, Itching, tremors 0.01% (2 people/13,454 people, 2 cases), chest discomfort, flatulence disease, discomfort in the solar plexus, abdominal distension, numbness, chills, muscle stiffness, head discomfort, worsening liver disease, hives, eczema, joint pain, knee abnormalities, arm weakness, proteinuria, increased blood creatinine, anxiety, insomnia, drowsiness, herpes simplex, One case each of blurred vision, high blood pressure, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, and heart failure was reported (reflected in reexamination results).
(2) As a result of analysis related to the cardiovascular risk of thiazolidinedione drugs, among the total 13,454 patients, 3,224 (23.96%) had cardiovascular comorbidities (including cerebrovascular disorders), and 10,230 (76.04%) patients did not have cardiovascular comorbidities. The incidence of cardiovascular adverse events and edema was statistically significantly higher in patients with cardiovascular comorbidities (see Table 14). (Please refer to the attached document for further details.)
(3) The incidence rate in patients with renal impairment (19.39%, 19/98 patients) was statistically significantly higher than the incidence rate in patients without renal impairment (2.68%, 358/13,356 patients) (p < 0.0001, odds ratio = 4.787).
(4) The incidence rate in patients with hepatic impairment (8.33%, 23/276 patients) was statistically significantly higher than the incidence rate in patients without hepatic impairment (2.69%, 354/13,178 patients) (p < 0.0001, odds ratio = 1.719).

5. General precautions
1) This drug has an antihyperglycemic effect only in the presence of insulin. Therefore, this drug should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Additionally, it is administered only to patients suspected of having insulin resistance. The standard for insulin resistance is a body mass index (BMI) of 24 or higher or an insulin secretion state of fasting blood insulin of 5 μU/mL or higher.
2) Bladder cancer: As a result of a 2-year carcinogenicity test, bladder tumors were observed in male rats. In two 3-year clinical trials of this drug using placebo or glyburide as comparators, bladder cancer was reported in 5 out of 3,679 patients (0.14%) who did not take this drug, and in 16 out of 3,656 patients (0.44%) who took this drug. After excluding patients who had been exposed to the test drug for less than 1 year at the time of bladder cancer diagnosis, there were 6 cases (0.16%) for this drug and 2 cases (0.05%) for placebo.
In the 5-year interim report of the ongoing 10-year observational Cocht trial, a non-significant increased risk of bladder cancer was observed for subjects exposed to this drug compared with subjects not exposed to this drug (HR 1.2 [95% CI 0.9 to 1.5]). Compared with no exposure to this drug, exposure to treatment with this drug for more than 12 months was associated with an increased risk (HR 1.4 [95% CI 0.9 to 2.1]), and use of this drug for more than 24 months reached statistical significance (HR 1.4 [95% CI 1.03 to 2.0]). Interim results for this trial showed that taking this drug for more than 12 months increased the relative risk of developing bladder cancer by 40%, which equates to an absolute increase of 3 cases per 10,000 (from about 7 cases per 10,000 people without taking this drug to about 10 cases per 10,000 people with this drug).
There are insufficient data to determine whether pioglitazone is a tumor promoting factor for bladder cancer. Therefore, this drug should not be used in patients with active bladder cancer, and this drug should not be used in patients with bladder cancer or a history of bladder cancer.
3) Hypoglycemia: Patients receiving this drug concomitantly with insulin or other anti-diabetic drugs (especially insulin secretagogues such as sulfonylureas) may be at risk of hypoglycemia, and a dose reduction of the concomitantly administered anti-diabetic drug may be necessary to reduce the risk of hypoglycemia.
4) Cardiovascular system: In a placebo-controlled clinical trial in the United States that excluded patients with New York Heart Association Class 3 or 4 cardiac conditions, there was no increased incidence of serious adverse cardiac events associated with volume expansion in patients treated with this drug as monotherapy or in combination with a sulfonylurea or metformin versus placebo-treated patients. In an insulin combination study, a small number of patients with a history of cardiac disease developed congestive heart failure when this drug was administered in combination with insulin (see WARNINGS). This drug has not been studied in clinical trials in patients with New York Heart Association Class 3 or 4 cardiac conditions and is not indicated for treatment.
In post-marketing studies of this drug, cases of congestive heart failure have been reported in both patients with known and unknown prior cardiac disease.
5) Edema: In controlled clinical trials, edema was reported more frequently in patients receiving this drug compared to patients receiving placebo and was dose-related. In post-marketing experience, new onset or worsening of edema has been reported. For patients with edema, this drug should be used with caution (see Adverse Reactions section). Thiazolidinedione drugs, including this drug, can cause fluid retention, which can cause or worsen congestive heart failure, so this drug should be administered with caution in patients at risk for congestive heart failure. Patients receiving this drug should be monitored for signs and symptoms of congestive heart failure.
6) Ovulation: Like other thiazolidinediones, this drug may cause ovulation in some premenopausal anovulatory women taking this drug. As a result, these patients may be at increased risk of becoming pregnant while taking this medication. Therefore, appropriate contraception should be recommended to premenopausal women. Because this possible action has not been studied in clinical trials, its incidence is unknown.
7) Action on the liver: There have been post-marketing reports of fatal and non-fatal liver failure in patients taking this drug, but these reports did not contain sufficient information necessary to establish a causal relationship. There is no evidence of drug-induced hepatotoxicity in the controlled clinical trial data to date for this drug.
People with type 2 diabetes may have heart disease with fatty liver or incidental congestive heart failure, both of which can cause abnormal liver tests and may also present with other forms of liver disease, many of which can be treated or managed. Therefore, it is recommended to evaluate patients by obtaining liver test values ​​(serum ALT, AST, ALP, and total bilirubin) before starting treatment with this drug. Patients with abnormal liver tests should be cautious when starting treatment with this drug.
Perform liver tests promptly in patients who report symptoms that may indicate liver damage, including fatigue, loss of appetite, right upper abdominal discomfort, melanuria, or jaundice. In these clinical situations, if the patient exhibits abnormal liver tests (ALT greater than 3 times the upper limit of the normal range), treatment with this drug should be discontinued and investigation should be conducted to determine the possible cause. Treatment with this drug should not be resumed in these patients unless there is another cause for abnormal liver tests.
Patients with no other etiologies, serum ALT levels greater than 3 times the upper limit of the normal range, and serum total bilirubin levels greater than 2 times the upper limit of the normal range should not resume treatment with this drug due to the risk of severe drug-induced liver damage. In patients with less elevated serum ALT or bilirubin levels and for other reasons, treatment with this drug may be used with caution.
8) Macular edema: In post-marketing surveillance of this drug, macular edema was reported in diabetic patients receiving pioglitazone or other thiazolidinedione drugs. Some patients presented with blurred vision or reduced vision, while others were diagnosed during routine eye exams. Most patients presented with peripheral edema at the time macular edema was diagnosed. In some patients, symptoms of macular edema improved after discontinuation of thiazolidinedione drugs. People with diabetes should have regular eye exams by an ophthalmologist according to current standard treatment. Diabetic patients who report visual symptoms of any kind should promptly seek medical attention from an ophthalmologist, regardless of medications they are taking or other physical findings (see Adverse Reactions section).
9) Fracture: In the PROactive trial, 5,238 patients with a history of type 2 diabetes and macrovascular disease were randomly assigned to receive this drug (n = 2,605), forced titration of the drug dose up to 45 mg per day, or placebo (n = 2,633) in addition to standard treatment. During a mean follow-up period of 34.5 months, the incidence of fractures in women was 5.1% (44/870) with this drug compared to 2.5% (23/905) with placebo. These differences were observed after the first year of treatment and persisted throughout the trial period. The majority of fractures observed in female patients were nonvertebral fractures involving the lower extremities and distal upper limbs. No increased incidence of fractures was observed in men treated with this drug (1.7%) compared to placebo (2.1%). In post-marketing surveillance, fractures were reported in both men and women. During long-term treatment with this drug, the risk of fractures should be considered and attention should be paid to assessing and maintaining bone health according to current standard treatments.
10) Macrovascular complications: Clinical trials have not been conducted to determine whether this drug or other antidiabetic agents reduce the risk of macrovascular complications.
11) Laboratory tests: Fasting blood sugar (FPG) and glycated hemoglobin (HbA1C) measurements should be performed regularly to monitor blood sugar control and treatment response to this drug. Monitoring of liver enzymes is recommended in all patients prior to initiating therapy with this drug and at regular intervals thereafter based on the clinical judgment of the physician (see Actions for Adverse Reactions and General Precautions).
12) Patients with renal impairment: In patients with moderate (creatinine clearance 30 to 60 mL/min) to severe (creatinine clearance <30 mL/min) renal impairment, the serum elimination half-life of pioglitazone, M-III, and M-IV does not change when compared to normal subjects. Dosage adjustment is not recommended in patients with renal insufficiency (see Dosage and Administration).
13) Information for patients
It is important to instruct patients to follow their prescribed diet and have regular blood glucose and glycated hemoglobin (HbA1c) tests. Remind patients to consult their physician promptly during periods of stress, such as fever, trauma, infection or surgery, because treatment requirements may change.
Patients who experience unusually rapid weight gain or swelling while taking this medicine, or who develop shortness of breath or other symptoms of heart failure, should immediately report these symptoms to their doctor.
Patients should be informed that liver function blood tests will be performed at the doctor's clinical discretion before starting treatment and periodically thereafter. Patients should be advised to seek immediate medical attention for unexplained nausea, vomiting, abdominal pain, fatigue, loss of appetite, or dark urine.
Inform patients to take this medicine once daily, with or without food. If a daily dose is missed, do not take a double dose the following day.
When administered concurrently with insulin or oral hypoglycemic agents, the risk of hypoglycemia, its symptoms and treatment methods, and conditions that are likely to develop due to those symptoms must be explained to the patient and his or her family members.
As with other thiazolidinediones, therapy with this drug may cause ovulation in some premenopausal anovulatory women. As a result, these patients may be at increased risk of becoming pregnant while taking this medication. Therefore, appropriate contraception should be recommended to premenopausal women. Because this possible action has not been studied in clinical trials, its incidence is unknown.
Patients should be instructed to immediately notify their doctor if signs of gross hematuria or other symptoms, such as dysuria or urgency, develop or increase during treatment, as these symptoms may be due to bladder cancer.

6. Interaction
1) Strong CYP2C8 inhibitor
CYP2C8 inhibitors (e.g., gemfibrozil) significantly increase the exposure (area under the serum concentration-time curve, or AUC) and half-life of pioglitazone. A dose reduction may be necessary when coadministered with gemfibrozil or other strong CYP2C8 inhibitors.
2) CYP2C8 inducer
CYP2C8 inducers (e.g., rifampin) significantly reduce the exposure (AUC) of pioglitazone. Therefore, if a CYP2C8 inducer is started or discontinued during treatment with this drug, it may be necessary to change diabetes treatment based on clinical response.
3) Drug-drug interaction (please refer to the attached document for more details)

7. Administration to pregnant and lactating women
1) Pioglitazone was not teratogenic when administered at oral doses of up to 80 mg/kg in rats or up to 160 mg/kg in rabbits during the organogenesis period (approximately 17 and 40 times the maximum recommended oral dose for humans, respectively, based on mg/m2). Delayed parturition and embryonic toxicity (increased postimplantation loss, delayed development, decreased fetal weight) were observed in rats administered oral doses of 40 mg/kg/day (approximately 10 times the maximum recommended human oral dose based on mg/m2) or more. No functional or behavioral toxicity was found in rat offspring. Embryotoxicity was observed in rabbits at an oral dose of 160 mg/kg (approximately 40 times the maximum recommended oral dose for humans based on mg/m2). In rat offspring at oral doses greater than 10 mg/kg (approximately twice the maximum recommended human oral dose based on mg/m2), delayed postnatal growth due to weight loss was observed during late pregnancy and lactation.
There are no adequate and well-controlled clinical trials in pregnant women. In animal experiments, increased rates of postimplantation loss, delayed development, decreased fetal weight, and delayed delivery were observed at doses 10 to 40 times the maximum recommended human dose. This medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Abnormal blood sugar levels during pregnancy are associated with increased neonatal morbidity and mortality, as well as a high incidence of congenital malformations. It is recommended to use insulin during pregnancy to keep blood sugar levels as close to normal as possible.
2) It is not known whether this drug passes into human breast milk. Pioglitazone is secreted into the milk of lactating rats. Since many drugs pass into human milk and this drug has the potential to cause serious adverse reactions in breast-feeding infants, the importance of administering this drug to a nursing mother should be considered and a decision should be made whether to discontinue breastfeeding or to discontinue this drug.

8. Administration to children
The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.

9. Administration to elderly people
When three 16- to 26-week double-blind, placebo-controlled, monotherapy clinical trials were combined, a total of 92 patients (15.2%) who received this drug were over 65 years of age, and 2 patients (0.3%) were over 75 years of age. When two 16- to 24-week clinical trials of combined administration with sulfonylurea were combined, 201 patients (18.7%) who received this drug were over 65 years of age, and 19 patients (1.8%) were over 75 years of age. When two 16- to 24-week clinical trials were combined with metformin, 155 (15.5%) patients receiving this drug were over 65 years of age, and 19 (1.9%) were over 75 years of age. When combining two clinical trials of 16 to 24 weeks of concurrent administration with insulin, 272 (25.4%) patients who received this drug were over 65 years of age, and 22 (2.1%) were over 75 years of age.
In the PROactive clinical trial, 1,068 (41.0%) patients who received this drug were over 65 years of age, and 42 (1.6%) were over 75 years of age.
In pharmacokinetic studies of pioglitazone, no significant differences in pharmacokinetic parameters were observed between elderly and young patients. Although conclusions are limited by the small sample size of patients over 75 years of age, this clinical experience did not identify differences in safety and efficacy between older (over 65 years of age) and younger patients.
10. Treatment in case of overdose
During comparative clinical trials, one case of overdose of this drug was reported. A male patient took 120 mg/day for 4 days and 180 mg/day for the next 7 days. The patient denied any clinical symptoms during this period.
If an overdose event occurs, appropriate supportive care should be initiated according to the patient's clinical signs and symptoms.

11. Storage and handling precautions
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container and keep it tightly closed.

12. Others
1) Carcinogenicity, mutagenicity, fertility
A two-year carcinogenicity study was conducted in male and female rats at an oral dose of up to 63 mg/kg (approximately 14 times the maximum recommended human oral dose of 45 mg based on mg/m2). No drug-induced tumors were found in any organ except the bladder. Benign and/and malignant cellular neoplasms have been observed in male rats receiving doses greater than 4 mg/kg/day (approximately equivalent to the maximum recommended human oral dose on a mg/m2 basis). A 2-year carcinogenicity study was conducted in male and female mice at oral doses up to 100 mg/kg/day (approximately 11 times the maximum recommended oral dose for humans based on mg/m2). No drug-induced tumors were found in any organ.
Pioglitazone hydrochloride was not found to be mutagenic in a series of genotoxicity studies such as reverse mutation assay, mammalian cell chromosomal aberration assay (CHO/HPRT and AS52/XPRT), cytogenetic analysis using CHL cells, unscheduled DNA synthesis assay, and micronucleus assay.
No adverse effects on fertility were observed in male and female rats administered oral doses of up to 40 mg/kg (approximately 9 times the maximum recommended human oral dose based on mg/m2) of pioglitazone hydrochloride daily before and throughout mating and pregnancy.
2) Animal toxicity
Cardiac hypertrophy was observed in mice (100 mg/kg), rats (4 mg/kg or more), and dogs (3 mg/kg) administered orally with pioglitazone hydrochloride (approximately 11, 1, and 2 times the maximum recommended human oral dose based on mg/m2 in mice, rats, and dogs, respectively). In a 1-year rat study, early drug-related death due to apparent cardiac dysfunction occurred at an oral dose of 160 mg/kg/day (approximately 35 times the maximum recommended human oral dose on a mg/m2 basis). A 13-week study in monkeys showed cardiac hypertrophy at oral doses higher than 8.9 mg/kg (approximately 4 times the maximum recommended human oral dose on a mg/m2 basis), but not in a 52-week study at oral doses up to 32 mg/kg (approximately 13 times the maximum recommended human oral dose on a mg/m2 basis).

5. How to save
Store in a light-proof, airtight container at 25℃, avoiding moisture (15℃~30℃)

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 9items

No.Product NameDetailsDate of ChangeDownload
9Pictos Tab.Pictos tablets (precautions for use)2017.06.16HWPPrecautions for using Pictos tablets.hwp
8Pictos Tab.Pictos tablets (precautions for use)2016.08.08HWPPioglitazone hydrochloride single oral administration unification plan.hwp
7Pictos Tab.Pictos tablets (efficacy, dosage, usage, precautions...2013.12.30HWP2012 Pharmaceutical Literature Re-evaluation (Pictos Tablet).hwp
6Pictos Tab.Pictos tablets (precautions for use)2011.11.22Changes in precautions for using Pictos tablets.hwpFile under review
5Pictos Tab.Pictos tablets (precautions for use)2010.07.089. Change order for permit (Pictos) (2010.07.08).hwpFile under review
4Pictos Tab.Pictos tablets (precautions for use)2009.10.07HWP9. Change order for permit (Pictos) (2009.10.07).hwp
3Pictos Tab.Pictos tablets (precautions for use)2008.01.10HWP9. Change order for permit (Pictos) (2008.01.10).hwp
2Pictos Tab.Pictos tablets (precautions for use)2007.08.17HWP9. Change order for permit (Pictos) (2007.08.17).hwp
1Pictos Tab.Pictos tablets (precautions for use)2007.06.12HWP9. Change order for permit (Pictos) (2007.06.12).hwp